Anavex Life Sciences Corp.

NASDAQ:AVXL

Biotechnology

Healthcare
$0.72 -1.67%

-$0.04 today

Market cap
$66.69M
Beta
1.12
P/E (TTM)
-5.9
EPS (TTM)
-$0.45
52W Low $2.41High $13.99

Volume 1.06M

Average 1.39M

AVXL EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Anavex Life Sciences Corp.NASDAQ: AVXL

EBITDA · Q1 FY2026 · quarter ended Dec 2025

EBITDA remains negative

Q1 FY2026 EBITDA was -$5.66M, compared with -$13.58M a year earlier. Trailing-twelve-month EBITDA was -$38.87M.

Context

  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of $0 (+100.0%) for the fiscal year ending Sep 2026, a step up from the -7.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-$5.66M+12.7% QoQ
Last fiscal yearSep 2025
-$46.38M-7.8% YoY
LTMDec 2025
-$38.87M+24.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58.3%+100.0%+41.7 pp
1 year-7.8%+100.0%+107.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(46.38M) USD
Year-over-year change
-7.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How AVXL compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +24.6% is the 2nd highest of 10, against a peer median of -87.3%.
AVXL Competitors
EBITDA for AVXL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVXLAnavex Life Sciences Corp.LTM Dec 2025-$38.87M USD+24.6%——
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-$57.67M USD-232.5%—162.2%
VALNValneva SELTM Mar 2026-€90.14M EUR-119.6%—57.7%
MGTXMeiraGTx Holdings plcLTM Mar 2026-$95.72M USD+32.5%—120.0%
ABSIAbsci CorporationLTM Mar 2026-$106.84M USD-14.3%—5818.9%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026-$148.59M USD-85.2%——
ARVNArvinas, Inc.LTM Mar 2026-$216.5M USD-437.2%—242.2%
RGNXREGENXBIO Inc.LTM Mar 2026-$229.35M USD-87.3%—261.2%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026-$245.81M USD-69.1%——
ERASErasca, Inc.LTM Sep 2026-$305.05M USD-151.6%——
Peer median (excluding AVXL) —-87.3%—202.2%

Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development32.98M37.92M43.72M41.84M37.59M
Selling, General & Admin9.02M13.07M12.05M11.04M13.82M
Operating Expenses42M50.99M55.76M52.88M51.41M
Depreciation & Amortization00000
EBITDA(37.64M)(47.62M)(46.54M)(43M)(46.38M)
EBITDA Margin—————
Operating Income(42M)(50.99M)(55.76M)(52.88M)(51.41M)
Operating Margin—————
Interest Income26K947K6.52M7.32M4.68M
Interest Expense00964K00
Other Income / Expenses4.36M3.37M8.26M9.88M5.03M
Income Before Tax(37.64M)(47.62M)(47.51M)(43M)(46.38M)
Pre-Tax Margin—————
Income Tax Expense268K358K000
Net Income(37.91M)(47.98M)(47.51M)(43M)(46.38M)
Net Margin—————
EPS (Basic)(0.54)(0.62)(0.60)(0.52)(0.54)
EPS (Diluted)(0.54)(0.62)(0.60)(0.52)(0.54)
Weighted Avg Shares69.8M76.91M79.79M83.47M85.29M
Weighted Avg Shares (Diluted)69.8M76.91M79.79M83.47M85.29M

Anavex Life Sciences Corp.

NASDAQ:AVXL

Intrinsic Alpha fair value

Locked

Current Price

$0.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.